Adriamycin, cyclophosphamide, vindesine, valproic acid — Competitive Intelligence Brief

Adriamycin, cyclophosphamide, vindesine, valproic acid (Adriamycin, cyclophosphamide, vindesine, valproic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline antibiotic, alkylating agent, vinca alkaloid, histone deacetylase inhibitor. Area: Oncolo

phase 2 anthracycline antibiotic, alkylating agent, vinca alkaloid, histone deacetylase inhibitor DNA, tubulin, histone deacetylases Oncology Small molecule

Target snapshot

Adriamycin, cyclophosphamide, vindesine, valproic acid (Adriamycin, cyclophosphamide, vindesine, valproic acid) — European Lung Cancer Working Party. Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adriamycin, cyclophosphamide, vindesine, valproic acid TARGET	Adriamycin, cyclophosphamide, vindesine, valproic acid	European Lung Cancer Working Party	phase 2	anthracycline antibiotic, alkylating agent, vinca alkaloid, histone deacetylase inhibitor	DNA, tubulin, histone deacetylases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthracycline antibiotic, alkylating agent, vinca alkaloid, histone deacetylase inhibitor class)

1. European Lung Cancer Working Party · 1 drug in this class